Crispr Therapeutics Products 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"CRISPR Therapies Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR Therapies Market.

The CRISPR Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the CRISPR Therapies Pipeline Report:

*
Companies across the globe are diligently working toward developing novel CRISPR Therapies treatment therapies with a considerable amount of success over the years.

*
CRISPR Therapies companies working in the treatment market are Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others, are developing therapies for the CRISPR Therapies treatment

*
Emerging CRISPR Therapies therapies in the different phases of clinical trials are- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others are expected to have a significant impact on the CRISPR Therapies market in the coming years.

*
In May 2025, Researchers at the University of Minnesota have completed the first human clinical trial using a CRISPR/Cas9 gene-editing method aimed at boosting the immune system's ability to combat advanced gastrointestinal (GI) cancers. The findings, recently published in Lancet Oncology, demonstrate promising safety and potential effectiveness of the therapy. In this study, the team employed CRISPR/Cas9 to modify tumor-infiltrating lymphocytes (TILs), a type of immune cell. By disabling the CISH gene, the modified TILs showed an improved capacity to identify and attack cancer cells.

*
In January 2025, Scientists at the Experimental and Clinical Research Center (ECRC) in Berlin are advancing a targeted gene-editing therapy for muscular dystrophy. Preclinical studies conducted by the Spuler Lab, recently published in Nature Communications, have laid the groundwork for upcoming first-in-human clinical trials. The ECRC, a collaboration between the Max Delbruck Center and Charite - Universitatsmedizin Berlin, has created a promising gene-editing strategy aimed at restoring the function of a key protein vital for muscle repair and regeneration in patients suffering from muscular dystrophy.

CRISPR Therapies Overview

CRISPR therapies are a type of gene-editing treatment that use the CRISPR-Cas9 technology to precisely modify DNA within cells. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) allows scientists to target and correct faulty genes responsible for various genetic disorders. These therapies hold promise for treating conditions like sickle cell anemia, cancer, and certain inherited diseases by either repairing or disabling the problematic gene. CRISPR-based therapies are still largely in clinical trial phases but represent a revolutionary approach to personalized and potentially curative medicine.

Get a Free Sample PDF Report to know more about CRISPR Therapies Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight [https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging CRISPR Therapies Drugs Under Different Phases of Clinical Development Include:

*
BEAM-301: Beam Therapeutics

*
TNG260: Tango Therapeutics

*
CTX 130: CRISPR therapeutics

*
CB-010: Caribou Biosciences, Inc.

*
KSQ-4279: KSQ Therapeutics

*
NTLA-2002: Intellia Therapeutics, Inc.

*
LBP-EC01: Locus Biosciences

*
CTX001: CRISPR Therapeutic

CRISPR Therapies Route of Administration

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

*
Molecule Type

CRISPR Therapies Molecule Type

CRISPR Therapies Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

CRISPR Therapies Pipeline Therapeutics Assessment

*
CRISPR Therapies Assessment by Product Type

*
CRISPR Therapies By Stage and Product Type

*
CRISPR Therapies Assessment by Route of Administration

*
CRISPR Therapies By Stage and Route of Administration

*
CRISPR Therapies Assessment by Molecule Type

*
CRISPR Therapies by Stage and Molecule Type

DelveInsight's CRISPR Therapies Report covers around 30+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further CRISPR Therapies product details are provided in the report. Download the CRISPR Therapies pipeline report to learn more about the emerging CRISPR Therapies therapies [https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the CRISPR Therapies Therapeutics Market include:

Key companies developing therapies for CRISPR Therapies are - eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Inscripta, Synthego, Inari, Ligandal, CRISPR Therapeutics, Mammoth Biosciences, Poseida Therapeutics, Beam Therapeutics, Pairwise, Sherlock Biosciences, and others

CRISPR Therapies Pipeline Analysis:

The CRISPR Therapies pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR Therapies with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Therapies Treatment.

*
CRISPR Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
CRISPR Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR Therapies market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about CRISPR Therapies drugs and therapies [https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

CRISPR Therapies Pipeline Market Drivers

*
New drugs are discovered employing the novel ways to treat diseases, CRISPR/Cas9 provides extensive opportunities for programmable gene editing are some of the important factors that are fueling the CRISPR Therapies Market.

CRISPR Therapies Pipeline Market Barriers

*
However, unwanted immune responses, off-target effects, CRISPR has tangible progress for localized administration and other factors are creating obstacles in the CRISPR Therapies Market growth.

Scope of CRISPR Therapies Pipeline Drug Insight

*
Coverage: Global

*
Key CRISPR Therapies Companies: Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others

*
Key CRISPR Therapies Therapies: BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others

*
CRISPR Therapies Therapeutic Assessment: CRISPR Therapies current marketed and CRISPR Therapies emerging therapies

*
CRISPR Therapies Market Dynamics: CRISPR Therapies market drivers and CRISPR Therapies market barriers

Request for Sample PDF Report for CRISPR Therapies Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. CRISPR Therapies Report Introduction

2. CRISPR Therapies Executive Summary

3. CRISPR Therapies Overview

4. CRISPR Therapies- Analytical Perspective In-depth Commercial Assessment

5. CRISPR Therapies Pipeline Therapeutics

6. CRISPR Therapies Late Stage Products (Phase II/III)

7. CRISPR Therapies Mid Stage Products (Phase II)

8. CRISPR Therapies Early Stage Products (Phase I)

9. CRISPR Therapies Preclinical Stage Products

10. CRISPR Therapies Therapeutics Assessment

11. CRISPR Therapies Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. CRISPR Therapies Key Companies

14. CRISPR Therapies Key Products

15. CRISPR Therapies Unmet Needs

16 . CRISPR Therapies Market Drivers and Barriers

17. CRISPR Therapies Future Perspectives and Conclusion

18. CRISPR Therapies Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=crispr-therapeutics-products-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-egenesis-intellia-therapeutics-editas-medicine-caribou-biosciences-inscripta-synthego]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.